Biologic viral safety is entering a new phase. Updated global ICH guidance is reshaping how manufacturers approach risk based controls, modern analytics and manufacturing innovation. In this PharmTech feature, John M. e...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Reimagining vaccine development with AI
Explore how AI is accelerating vaccine development, improving speed, precision, and global readiness.
-
Aging with HIV: What the next major challenge is for drug development
As people with HIV live longer due to ART, new challenges are emerging. Aging with HIV is linked to higher risks of comorbidities, chronic inflammation, and drug interactions, while gaps in clinical trial inclusion and care models highlight the need for more integrated, patient-centered treatment strategies.
-
From study end to long-term insight: Choosing the right vaccine follow-up strategy
Navigating long‑term vaccine follow‑up isn’t one‑size‑fits‑all; explore the key questions that help determine the right mix of traditional studies and tokenisation.
-
Beyond viral suppression: Next-generation HIV therapeutics target reservoirs, broadly neutralising antibodies, and gene editing
Long-acting injectables have transformed HIV management, but viral suppression alone is not enough. Researchers are advancing mRNA vaccines, broadly neutralizing antibodies, latency-reversing agents, pediatric immune strategies, and gene editing to eliminate reservoirs and achieve remission. Here’s how next-generation HIV therapeutics aim to move beyond lifelong ART.
-
Investing in anti-HIV: How anti-HIV therapeutic developers can reshape the future of HIV control
Despite decades of progress transforming HIV from a fatal diagnosis into a manageable chronic condition, today’s antiretroviral therapies still face a stubborn barrier: They work brilliantly in theory but fall short when access, adherence, and real-world challenges get in the way.
-
Multidrug-resistant infections necessitate bacteriophage treatment: Can we get there in time?
As antibiotic resistance surges globally, bacteriophage therapy is emerging as a promising alternative for treating multidrug-resistant infections. To scale this life-saving approach, investment in phage development, clinical trials, and diagnostic infrastructure is urgently needed.
-
Early-phase study design considerations for long-term follow-up in vaccine clinical trials
ICON experts discuss why strategic early planning is key to long-term follow-up in vaccine trials—driving stronger protocols, regulatory alignment, and meaningful outcomes.
-
Hot shots: The power and potential of study tokenisation for vaccine research and post-commercialisation
Discover how clinical trial tokenisation helps sponsors gain patient insights and enable long-term data collection—without adding burden to patients or sites.
-
Overcoming challenges with maternal vaccine trials
In this article from pharmaphorum, Dinah Knotts, VP of Project Management in Vaccines and Infectious Diseases and Mitsu Rana, Senior Director of Project Management outline some of the challenges with maternal vaccine trials and how with careful planning and execution by researchers, these can be overcome throughout the trial process.
-
Decoding pandemic precision: From SARS-CoV-2 to influenza vaccination strategies
The need for public health officials to be able to model the spread of infectious diseases has never been more apparent than in the early days of the SARS-CoV-2 pandemic, but what needs to change? Read the article by ICON epidemiologist Dr. Richard Pitman in Open Access Government.
